The HALT Fentanyl Act makes it illegal to manufacture, distribute, or possess fentanyl-related substances by adding them to Schedule I of the Controlled Substances Act. This is a broad approach that targets not just fentanyl itself, but also any chemical variations of fentanyl that drug makers create to try to get around existing laws. Essentially, if a substance is chemically similar to fentanyl—even with small modifications—it becomes illegal unless the government specifically exempts it or lists it in a different schedule.

The law affects everyday people by making it a federal crime to handle these substances without authorization, with serious penalties for trafficking or possession. For legitimate researchers and medical professionals, the bill creates a streamlined process to study fentanyl-related substances for approved purposes like developing new medications. Researchers who are already registered to study controlled drugs can now notify the Attorney General and begin research on newly scheduled fentanyl-related substances within 30 days, rather than waiting for lengthy approval processes. They can also conduct small-scale manufacturing activities (like creating extracts or testing dosage forms) as part of their research without needing separate manufacturing licenses.

The practical impact is twofold: it closes loopholes that drug traffickers exploit by constantly creating new fentanyl variations to stay ahead of the law, while simultaneously making it easier for legitimate scientists and doctors to research these substances for medical breakthroughs. The government has one year to write detailed rules explaining how all these changes will work in practice.

HALT Fentanyl Act

Griffith, H. Morgan

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including <ul> <li>permitting a single registration for related research sites in certain circumstances, </li> <li>waiving the requirement for a new inspection in certain situations, and </li> <li>allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. </li> </ul>